Cargando…
Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
The survival of multiple myeloma patients has improved significantly over the last several decades. However, the median overall survival of these patients remains less than 5 years. In this report, we discuss 4 cases of multiple myeloma patients that showed long survival. Interestingly, these patien...
Autores principales: | Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Azuma, Yoshiko, Tsubokura, Yukie, Konishi, Akiko, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Ito, Tomoki, Nomura, Shosaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662964/ https://www.ncbi.nlm.nih.gov/pubmed/29118703 http://dx.doi.org/10.1159/000481166 |
Ejemplares similares
-
Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020) -
Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017) -
Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
por: Nakaya, Aya, et al.
Publicado: (2017) -
Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
por: Ito, Tomoki, et al.
Publicado: (2018) -
Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia
por: Hotta, Masaaki, et al.
Publicado: (2018)